Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retractable TechnologiesRVP +0.66%39 EV-to-EBIT is 2.26 as of Jul. 27, 2026, which is 93% above its 10-year median of 1.17. GuruFocus rates RVP with a GF Score™ of 39/100 and a GF Value™ of $0.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Retractable Technologies ranks better than 96.57% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Retractable Technologies's Enterprise Value for the quarter that ended in Mar. 2026 was $-14.67 Mil.
Retractable Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retractable Technologies EV-to-EBIT Related Terms
Retractable Technologies EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Retractable Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Retractable Technologies EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Retractable Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Retractable Technologies's EV-to-EBIT falls into.
Retractable Technologies's current Enterprise Value is $-13.99 Mil.
Retractable Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Retractable Technologies (RVP) has a EV-to-EBIT of 2.26 as of Jul. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Retractable Technologies and its competitors. This is 93% above median its historical median of 1.17. According to the industry distribution chart, Retractable Technologies ranks #16 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 3.4%.
Is Retractable Technologies' EV-to-EBIT too high?
Retractable Technologies' current EV-to-EBIT of 2.26 is 93% above median its 10-year median of 1.17. The Medical Devices & Instruments industry median EV-to-EBIT is 18.40. Retractable Technologies' value of 2.26 is 87.7% below this industry median. Based on the distribution chart, Retractable Technologies ranks #16 out of 466 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Retractable Technologies has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Retractable Technologies' EV-to-EBIT compare to ZJYL and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Retractable Technologies ranks #16 out of 466 companies for EV-to-EBIT. This places Retractable Technologies in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.40. Retractable Technologies' value of 2.26 is 87.7% below this benchmark. While the company's 10-year median is 1.17 vs. the industry median of 18.40, Retractable Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.40, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Retractable Technologies's current EV-to-EBIT of 2.26 is 87.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Retractable Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Retractable Technologies's current EV-to-EBIT is 2.26, which is 93% above median its own 10-year median of 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Retractable Technologies stock overvalued right now?
Based on GuruFocus' analysis, Retractable Technologies (RVP) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.76, compared to a current price of $0.68 — trading 9.9% below its estimated fair value. The current EV-to-EBIT is 2.26, which is 93% above median its 10-year median of 1.17 and 87.7% below the Medical Devices & Instruments industry median of 18.40. Retractable Technologies' overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Retractable Technologies (RVP), the current EV-to-EBIT is 2.26 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Retractable Technologies (RVP) Overvalued in 2026?
Based on GuruFocus' analysis, Retractable Technologies stock appears to be undervalued.
The current stock price of $0.68 is trading 9.9% below its estimated GF Value™ of $0.76.
GuruFocus considers Retractable Technologies to be Modestly Undervalued.
Key valuation signals for RVP:
EV-to-EBIT: 2.26 (93% above median its 10-year median of 1.17)
GF Value™: $0.76 vs. price of $0.68 (9.9% below fair value)
Industry Position: 87.7% below the Medical Devices & Instruments median (#16 of 466)
No single metric tells the full story. See the RVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
39GF Score
Get the complete analysis for RVP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVP has been successfully added to your 
